TransMedics outlines 20–25% 2026 revenue growth target while advancing OCS programs and European expansion
View original at seekingalpha.comTransMedics outlines 20–25% 2026 revenue growth target while advancing OCS programs and European expansion Earnings Call Insights: TransMedics Group, Inc…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
TransMedics delivered an operating profit of approximately $21.3 million in Q4, representing approximately 13.2% of total revenue
80% confidenceThe makers of that styrofoam box is refusing to randomize their technology to ours in ENHANCE Part B
80% confidenceTransMedics has huge opportunities ahead but also faces a few challenges and moving dynamics, which have been factored into guidance
80% confidenceBy organ, liver contributed $127 million, heart $26 million and lung $2 million in Q4
80% confidenceTransMedics delivered an operating profit of approximately $21.3 million in Q4, representing approximately 13.2% of total revenue for fourth quarter while making substantial investments to fuel growth
80% confidenceAlmost 50% of incremental 2026 investment is driven by three transitory elements
80% confidenceBy organ, liver contributed $127 million, heart $26 million and lung $2 million in Q4 2025
80% confidenceNOP Connect 2.0 is showing efficiency in management and billing, though these are early days
80% confidenceTransMedics is just getting started and has sights focused on new peaks
80% confidenceOperating profit of approximately $21.3 million in Q4 represented approximately 13.2% of total revenue
80% confidenceNOP Connect 2.0 is showing efficiency in management and billing, though in early stages
80% confidenceU.S. transplant revenue grew approximately 11% sequentially to $155 million
80% confidenceOCS was responsible for 5,139 U.S. transplants in 2025, up from 3,735 in 2024
80% confidenceOCS Liver reached 36% of U.S. liver transplant volume, up from 26% in 2024, and OCS Heart comprised 18% of heart transplants, up from 17%
80% confidenceU.S. transplant revenue grew approximately 11% sequentially to $155 million in Q4 2025
80% confidenceThe makers of styrofoam box competitor are refusing to randomize their technology against OCS in ENHANCE Part B
80% confidence2026 operating margins expected to be up to approximately 250 basis points below 2025 full year levels, primarily reflecting timing and scale of investments
80% confidenceAlmost 50% of incremental investment in 2026 is driven by three elements that are transitory by nature
80% confidenceTransMedics delivered an operating profit of approximately $21.3 million in Q4, representing approximately 13.2% of total revenue
80% confidenceCompany is not seeing competitive dynamics impacting ability to execute in 2026 and beyond
80% confidenceOCS Liver reached 36% of U.S. liver transplant volume in 2025, up from 26% in 2024
80% confidenceTotal revenue for Q4 2025 was $160.8 million, representing approximately 32% growth year-over-year and approximately 12% sequential growth from Q3 2025
80% confidenceCompany is laser-focused on ensuring successful execution of initiatives throughout 2026
80% confidenceAlmost 50% of incremental 2026 investment is driven by three transitory elements
80% confidenceTotal revenue for Q4 2025 was $160.8 million, representing approximately 32% growth year-over-year and approximately 12% sequential growth from Q3 2025
80% confidenceLiver share gains are pure TransMedics execution excellence
80% confidenceTransMedics delivered 'our best operational performance to date' and achieved results despite external challenges earlier in the year designed to distract and disrupt sustained growth
80% confidenceThe makers of the styrofoam box technology are refusing to randomize their technology against TransMedics in ENHANCE Part B trial
80% confidenceTransMedics achieved its best operational performance to date in Q4 2025 despite external challenges designed to distract and disrupt growth
80% confidenceMost lung centers were waiting to see FDA approval before launching into DENOVO program
80% confidence